Fully funded by 
Content independently selected
INTERACT trial shows radiotherapy has similar efficacy, less toxicity.
An 11-year population-based propensity-matched analysis.
Previous recommendations covered basic principles and technology and clinical applications.
Delay could be most detrimental when hemoglobin levels are high.
Data from the phase 3 KLASS-01 randomized trial.
Resection boosts survival odds in rare tumor.
Tailored exercise augmented pathological tumor regression.
Large cohort study shows 52% lower risk for death, 34% reduced risk for HCC.
Recommendations aim to optimize limited resources.
Rare cancer has no evidence-based guidelines.
Liver, lung metastases match findings from the primary tumor.
No PFS benefit in patients receiving cisplatin plus fluoropyrimidine chemotherapy.
Oncologic outcomes similar to that of open surgery for tumors larger than 8 cm.
Clinical characteristics could guide strategy.
Presence can help determine surgical strategy.
Findings also refute suggestions of more aggressive disease.
Patient selection could avoid oxaliplatin-induced neuropathy.
